Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [LAI]) formulations are the mainstay of schizophrenia treatment. However, the dearth of…

Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of COPD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total COPD prevalent cases for each country,…

Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…

Clarivate Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NBP patient populations covering 171 countries and more than 99% of…

Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a type of B-cell non-Hodgkin’s lymphoma and represents the most common form of leukemia in adults. The R/R CLL treatment…

Clarivate Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and…

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. To address this risk factor, physicians use a range of lipid-modifying…

Eisai / Biogen’s Leqembi is set to capitalize on the unfulfilled potential for a disease-modifying therapy (DMT) for Alzheimer’s disease (AD), and additional anti-Aβ monoclonal antibodies (…